Patch for Hyperactive Children Nears Approval

The FDA told the manufacturer of the first skin patch to treat attention deficit hyperactivity disorder in children that the agency would approve the product if certain conditions were met, the company said.

In a letter to Noven Pharmaceuticals Inc., the Food and Drug Administration included proposed changes to how the patch is labeled, the Miami-based company said. The FDA also asked that the company conduct surveillance and study of the product once it is on the market. The patch would be sold under the name Daytrana.